Humana (HUM) Stock
US health insurer with Medicare Advantage and care services. Here's the price, business snapshot, and what's worth knowing about Humana in May 2026.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It's Moving
Humana’s move is being driven by a split analyst backdrop, with recent upgrades and high-end targets pointing to renewed confidence.
- UBS recently maintained its view on Humana and set a fresh target, adding to the stream of updates that have kept the name active and helped fuel debate around the stock’s near-term direction.
- Deutsche Bank’s May 20 target was one of the more bullish calls in the latest batch, reinforcing the market’s view that some analysts see meaningful upside if operating trends stabilize.
- The broader analyst picture remains mixed, with consensus targets ranging widely, which suggests investors are weighing potential recovery against ongoing uncertainty in the managed-care outlook.
Humana’s move is being driven by a split analyst backdrop, with recent upgrades and high-end targets pointing to renewed confidence.
- UBS recently maintained its view on Humana and set a fresh target, adding to the stream of updates that have kept the name active and helped fuel debate around the stock’s near-term direction.
- Deutsche Bank’s May 20 target was one of the more bullish calls in the latest batch, reinforcing the market’s view that some analysts see meaningful upside if operating trends stabilize.
- The broader analyst picture remains mixed, with consensus targets ranging widely, which suggests investors are weighing potential recovery against ongoing uncertainty in the managed-care outlook.
When is the next earnings date for Humana (HUM)?
Humana’s next earnings date is expected on July 29, 2026, before the market opens. The report should cover Q2 2026. This date is an estimate based on the company’s typical reporting pattern, as the exact release has not been formally confirmed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Humana's stock, as its target price is lower than the current price.
Financial Health
Humana is performing well with strong profits and cash flow, indicating a healthy financial position.
Dividend
Humana's dividend yield of 1.15% is below average, indicating limited income from dividends. If you invested $1000, you would be paid $11.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring HUM
Government Shutdown Impact: Defensive Stocks Explained
A U.S. government shutdown has been triggered by a congressional budget impasse, creating economic uncertainty. This theme focuses on companies in defensive sectors that may prove resilient to the resulting market volatility and disruptions in federal spending.
Published: October 2, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketDefensive Plays Amid Fed Turmoil
The removal of a Federal Reserve governor has created political and financial uncertainty, shaking confidence in the central bank's stability. This environment could create opportunities for investments in defensive sectors and assets that are traditionally seen as safe havens during periods of market volatility.
Published: August 26, 2025
Explore BasketFollowing Buffett's Healthcare Bet
Warren Buffett's Berkshire Hathaway is making a major $2.1 billion bet on UnitedHealth, signaling a strategic shift toward the healthcare sector. This theme focuses on other health insurers and healthcare providers that could benefit from this renewed investor confidence.
Published: August 15, 2025
Explore BasketHealthcare In The Crosshairs: Insurers Under Scrutiny
The Department of Justice is investigating UnitedHealth Group's Medicare billing, creating uncertainty for the nation's largest insurer. This situation presents a potential opportunity for rival health insurers to gain market share and for compliance-focused companies that help the industry navigate complex regulations.
Published: July 25, 2025
Explore BasketHealthcare Billing Integrity
This group of stocks includes companies positioned to benefit from increased focus on healthcare billing compliance. Carefully selected by professional analysts, these stocks represent both healthcare tech providers offering compliance solutions and competing insurers who may gain market share amid regulatory scrutiny.
Published: July 11, 2025
Explore BasketMedicaid Politics
Discover companies whose fortunes are closely tied to government healthcare funding decisions. These carefully selected stocks represent businesses with significant exposure to Medicaid, now facing heightened legislative uncertainty after Senator Tillis's retirement.
Published: June 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
